PBM
IMUX icon

Propel Bio Management’s Immunic IMUX Stock Holding History

Propel Bio Management’s Portfolio IMUX Stock Details IMUX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5M Buy
325,022
+90,544
+39% +$1.12M 2.61% 13
2026
Q1 		$2.62M Buy
+234,478
New +$2.1M 1.65% 24

Other funds holding IMUX

Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $624M AUM 250.2% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $2.7B AUM 88.53% 1-Year Est. Return
LCM
Laurion Capital Management New York $3.9B AUM 75.03% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JHC
Jones Hill Capital New York $470M AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.9B AUM 169.69% 1-Year Est. Return

Propel Bio Management's IMUX Position: Q2 2026 in Review

Propel Bio Management increased its Immunic (IMUX) stake by 39% in Q2 2026, buying an estimated $1.12M and bringing the position to 325,022 shares worth $5M. The position accounts for 2.61% of the portfolio, ranked #13.

Propel Bio Management first reported a position in IMUX in Q1 2026 and has held it in 2 quarters since. 55 funds tracked by Wall St. Rank hold IMUX as of Q2 2026.

  • Propel Bio Management held 325,022 shares of Immunic worth $5M as of Q2 2026.
  • Propel Bio Management bought 90,544 Immunic shares in Q2 2026, an estimated $1.12M.
  • Immunic made up 2.61% of Propel Bio Management's portfolio in Q2 2026, its #13 holding.
  • Propel Bio Management first reported a position in Immunic in Q1 2026 and has held it in 2 quarters since.
  • 55 funds tracked by Wall St. Rank held Immunic as of Q2 2026.

Based on Propel Bio Management's 13F filing for Q2 2026, filed 13 Aug 2026.